Fundraising Fox
Timberlyne
1 known investors
Find your way into Timberlyne
Sign up to see every warm intro you have to Timberlyne
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Timberlyne team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
Investors · 1
Frequently asked questions
- What does Timberlyne do?
- Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
- Who are Timberlyne's investors?
- Timberlyne's investors include Bain Capital Life Sciences.